Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$41.99 - $62.38 $3.81 Million - $5.66 Million
-90,681 Reduced 36.33%
158,931 $9.34 Million
Q3 2023

Nov 13, 2023

BUY
$27.8 - $45.35 $861,049 - $1.4 Million
30,973 Added 14.17%
249,612 $10.9 Million
Q2 2023

Aug 11, 2023

BUY
$36.13 - $49.49 $1.63 Million - $2.23 Million
45,123 Added 26.01%
218,639 $7.9 Million
Q1 2023

May 11, 2023

SELL
$36.54 - $54.26 $714,612 - $1.06 Million
-19,557 Reduced 10.13%
173,516 $6.45 Million
Q4 2022

Feb 13, 2023

BUY
$41.27 - $98.62 $4.6 Million - $11 Million
111,361 Added 136.28%
193,073 $8.75 Million
Q3 2022

Nov 14, 2022

BUY
$59.5 - $86.7 $1.01 Million - $1.48 Million
17,048 Added 26.36%
81,712 $5.71 Million
Q2 2022

Aug 12, 2022

SELL
$39.16 - $88.71 $60,188 - $136,347
-1,537 Reduced 2.32%
64,664 $4.34 Million
Q1 2022

May 13, 2022

BUY
$75.82 - $150.97 $2.05 Million - $4.09 Million
27,070 Added 69.18%
66,201 $5.44 Million
Q4 2021

Feb 10, 2022

BUY
$132.01 - $190.29 $2.68 Million - $3.87 Million
20,312 Added 107.93%
39,131 $5.74 Million
Q3 2021

Nov 10, 2021

BUY
$132.13 - $177.45 $483,331 - $649,112
3,658 Added 24.13%
18,819 $3.33 Million
Q2 2021

Aug 10, 2021

SELL
$144.0 - $179.73 $341,856 - $426,679
-2,374 Reduced 13.54%
15,161 $2.45 Million
Q1 2021

May 10, 2021

BUY
$158.92 - $221.61 $2.16 Million - $3.02 Million
13,623 Added 348.24%
17,535 $3 Million
Q4 2020

Feb 10, 2021

SELL
$162.05 - $240.27 $1.8 Million - $2.67 Million
-11,109 Reduced 73.96%
3,912 $859,000
Q3 2020

Nov 13, 2020

BUY
$113.26 - $167.27 $645,582 - $953,439
5,700 Added 61.15%
15,021 $2.49 Million
Q2 2020

Aug 07, 2020

BUY
$72.01 - $120.39 $374,956 - $626,870
5,207 Added 126.57%
9,321 $1.06 Million
Q1 2020

May 15, 2020

SELL
$69.78 - $116.21 $2.15 Million - $3.58 Million
-30,837 Reduced 88.23%
4,114 $316,000
Q4 2019

Feb 10, 2020

SELL
$70.76 - $128.86 $2.89 Million - $5.26 Million
-40,816 Reduced 53.87%
34,951 $4.5 Million
Q3 2019

Nov 14, 2019

BUY
$77.91 - $109.6 $1.82 Million - $2.56 Million
23,314 Added 44.45%
75,767 $5.9 Million
Q2 2019

Aug 09, 2019

SELL
$59.49 - $104.71 $1.13 Million - $1.99 Million
-19,043 Reduced 26.64%
52,453 $5.4 Million
Q1 2019

May 15, 2019

BUY
$43.65 - $78.95 $3.12 Million - $5.64 Million
71,496 New
71,496 $5.24 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.